Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteome | 4 | 2022 | 1799 | 0.660 |
Why?
|
| Cytosine | 1 | 2019 | 216 | 0.640 |
Why?
|
| Metabolome | 4 | 2023 | 895 | 0.630 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 11725 | 0.550 |
Why?
|
| Metabolomics | 7 | 2023 | 1484 | 0.540 |
Why?
|
| Blood Glucose | 2 | 2022 | 6256 | 0.330 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 5751 | 0.300 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2021 | 859 | 0.260 |
Why?
|
| Proteomics | 3 | 2023 | 3638 | 0.260 |
Why?
|
| Genomics | 1 | 2020 | 5720 | 0.240 |
Why?
|
| Oleic Acids | 1 | 2023 | 70 | 0.220 |
Why?
|
| Chemokine CX3CL1 | 1 | 2021 | 58 | 0.200 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2023 | 251 | 0.180 |
Why?
|
| Hypercalcemia | 1 | 2022 | 409 | 0.180 |
Why?
|
| Carnitine | 1 | 2019 | 246 | 0.160 |
Why?
|
| Anti-Obesity Agents | 1 | 2021 | 217 | 0.160 |
Why?
|
| End Stage Liver Disease | 1 | 2022 | 314 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2022 | 694 | 0.150 |
Why?
|
| Amino Acids | 1 | 2023 | 1736 | 0.140 |
Why?
|
| Insulin Resistance | 2 | 2021 | 3864 | 0.140 |
Why?
|
| Coronary Disease | 2 | 2022 | 6077 | 0.140 |
Why?
|
| Prediabetic State | 1 | 2021 | 499 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2021 | 727 | 0.130 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 12261 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2022 | 1253 | 0.120 |
Why?
|
| Cardiovascular Diseases | 4 | 2023 | 15165 | 0.110 |
Why?
|
| Obesity | 4 | 2023 | 12745 | 0.110 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 1222 | 0.100 |
Why?
|
| Overweight | 1 | 2021 | 2371 | 0.090 |
Why?
|
| Incidence | 4 | 2022 | 20947 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2022 | 12720 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 2872 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2022 | 2788 | 0.080 |
Why?
|
| Risk Factors | 5 | 2023 | 72290 | 0.080 |
Why?
|
| Homeostasis | 1 | 2019 | 3340 | 0.080 |
Why?
|
| Echocardiography | 1 | 2021 | 5102 | 0.080 |
Why?
|
| Zebrafish | 1 | 2019 | 2994 | 0.080 |
Why?
|
| Life Style | 1 | 2019 | 3835 | 0.080 |
Why?
|
| Humans | 21 | 2023 | 744343 | 0.080 |
Why?
|
| Glucose | 1 | 2019 | 4397 | 0.080 |
Why?
|
| Heart Failure | 2 | 2021 | 10900 | 0.070 |
Why?
|
| Nerve Degeneration | 1 | 2009 | 748 | 0.060 |
Why?
|
| alpha-Synuclein | 1 | 2009 | 723 | 0.060 |
Why?
|
| Aptamers, Peptide | 1 | 2022 | 28 | 0.050 |
Why?
|
| Diet | 1 | 2021 | 7939 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2022 | 6487 | 0.050 |
Why?
|
| Phenylalanine | 1 | 2023 | 365 | 0.050 |
Why?
|
| Leucine | 1 | 2023 | 561 | 0.050 |
Why?
|
| Homoarginine | 1 | 2021 | 9 | 0.050 |
Why?
|
| Orotic Acid | 1 | 2021 | 23 | 0.050 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 13989 | 0.050 |
Why?
|
| Fish Products | 1 | 2021 | 29 | 0.050 |
Why?
|
| Adult | 8 | 2022 | 214055 | 0.050 |
Why?
|
| Mississippi | 1 | 2021 | 88 | 0.050 |
Why?
|
| Middle Aged | 8 | 2022 | 213383 | 0.050 |
Why?
|
| Spermine | 1 | 2021 | 70 | 0.050 |
Why?
|
| Calcitonin | 1 | 2022 | 336 | 0.050 |
Why?
|
| Meat Products | 1 | 2021 | 99 | 0.050 |
Why?
|
| Uridine | 1 | 2021 | 146 | 0.050 |
Why?
|
| Polyamines | 1 | 2021 | 120 | 0.050 |
Why?
|
| Cystatin C | 1 | 2021 | 250 | 0.040 |
Why?
|
| Aged | 6 | 2022 | 163280 | 0.040 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 86 | 0.040 |
Why?
|
| Proline | 1 | 2021 | 458 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 13695 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2022 | 676 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2022 | 917 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2021 | 462 | 0.040 |
Why?
|
| Female | 9 | 2022 | 380194 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2021 | 436 | 0.040 |
Why?
|
| Animals | 5 | 2023 | 168757 | 0.040 |
Why?
|
| Diphosphonates | 1 | 2022 | 623 | 0.040 |
Why?
|
| Male | 8 | 2022 | 350118 | 0.040 |
Why?
|
| Cysteine | 1 | 2021 | 874 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 1623 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 12354 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 1157 | 0.030 |
Why?
|
| Parkinson Disease | 1 | 2009 | 2775 | 0.030 |
Why?
|
| Vegetables | 1 | 2021 | 1182 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2023 | 1809 | 0.030 |
Why?
|
| Antibodies | 1 | 2022 | 2460 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2023 | 23403 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2022 | 21746 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 21683 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 1573 | 0.030 |
Why?
|
| Collagen | 1 | 2021 | 2689 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2021 | 2132 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2019 | 2751 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2503 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2022 | 2265 | 0.020 |
Why?
|
| Weight Loss | 1 | 2021 | 2622 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 39050 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8642 | 0.020 |
Why?
|
| Health Behavior | 1 | 2021 | 2636 | 0.020 |
Why?
|
| Calcium | 1 | 2022 | 5756 | 0.020 |
Why?
|
| Heart | 1 | 2022 | 4467 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 2942 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2022 | 40561 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5097 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 2009 | 279 | 0.020 |
Why?
|
| Risk | 1 | 2021 | 9687 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2009 | 410 | 0.020 |
Why?
|
| Mice | 3 | 2023 | 81183 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2021 | 5007 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2021 | 12026 | 0.020 |
Why?
|
| Sex Factors | 1 | 2021 | 10397 | 0.020 |
Why?
|
| Insulin | 1 | 2019 | 6580 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 16365 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 15540 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 15519 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 19905 | 0.010 |
Why?
|
| Microtubules | 1 | 2009 | 1090 | 0.010 |
Why?
|
| United States | 2 | 2022 | 69872 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 21827 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 26385 | 0.010 |
Why?
|
| Prognosis | 1 | 2021 | 29063 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 25043 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9734 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 63114 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 14557 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 77449 | 0.010 |
Why?
|
| Disease Progression | 1 | 2009 | 13284 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 12072 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 9338 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17446 | 0.000 |
Why?
|
| Mutation | 1 | 2009 | 29786 | 0.000 |
Why?
|
Concepts
(126)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(42)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_